Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1024

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 3
Chunk 1024
---
 sold in the Initial Public Offering without the prior consent of the Company.

The Company’s Initial
Stockholders and Chardan Capital Markets, LLC (“Chardan”), the representative of the underwriters, have agreed not to propose
or vote in favor of an amendment to the Company’s Charter (A) that would modify the substance or timing of the Company’s obligation
to allow redemption in connection with the Business Combination or to redeem 100% of its Public Shares if the Company does not complete
a Business Combination within nine months or such other time period as the stockholders may approve from the closing of the
Initial Public Offering (the “Combination Period”) or (B) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination
activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such
an amendment. Pursuant to the Charter, if the Company is unable to complete a Business Combination within the Combination Period, the
Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly and as reasonably possible, but not more
than ten business days thereafter, redeem 100% of the outstanding Public Shares, at a per share price, payable in cash, equal to
the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously
released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of
then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the
right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption,
dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors
and the requirements of other applicable law.

F-8

OSR HOLDINGS, INC.

(f/k/a Bellevue Life Sciences Acquisition Corp.) 

NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024

The Sponsor, officers and directors have agreed
to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement
Shares held by them if the Company fails to complete a Business Combination within the Combination Period.